<p><strong>诺和诺德公司</strong> (NYSE: NVO) 和 <strong>Hims &amp; Hers Health Inc.</strong> (NYSE: HIMS) 据报道已经 结束了他们的公开争执，制药公司决定在远程医疗平台上销售其减肥药。</p>
<p>关于新合作伙伴关系的公告预计将在周一尽快发布，彭博社 报道 周五援引一位知情人士的话说。</p>
<p>上个月，诺和诺德起诉了 Hims &amp; Hers，因为后者开始推广其新减肥药的复合版本。该公司指控侵犯专利，引用了 Wegovy 中使用的成分。</p>
<p>在 2025 年，诺和诺德和 Hims &amp; Hers 也宣布了一项合作关系，但在平台拒绝停止推广复合 药物版本 后，制药公司突然终止了协议。</p>
<p>“我们始终与能够帮助改善慢性疾病患者获得 FDA 批准药物的公司进行对话。这些谈话是持续进行的，我们将在有最终细节可分享时进行讨论，” 诺和诺德的一位发言人通过电子邮件告诉 Benzinga。</p>
<p>Hims &amp; Hers 并未立即回应 Benzinga' 的评论请求。</p>
<h2><strong>减肥药市场压力加大</strong></h2>
<p>诺和诺德在肥胖药物市场面临激烈竞争。该 公司的最大竞争对手 是 <strong>礼来公司</strong> (NYSE: LLY) 和提供复合 GLP-1 药物版本的远程医疗平台。</p>
<p>由于近期供应短缺，竞争加剧。然而，美国食品药品监督管理局已表示计划加强对仿制减肥药的审查。</p>
<p><strong>价格动态：</strong> 在盘后交易中，Hims &amp; Hers Health 的股价上涨 39.77%，至 22 美元，而周五收盘时下跌 0.88%，为 15.74 美元。诺和诺德的股价周五收于 38.58 美元，下跌 1.25%，但在盘后交易中上涨 2.12%，至 39.40 美元，数据来自 Benzinga Pro。</p>
<p><strong>Benzinga 的边际股票排名</strong> 显示诺和诺德在短期、中期和长期内 表现疲软，尽管其质量评分在 76 百分位。</p>
<p><img src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06212821/Screenshot-2026-03-07-at-7.55.13%E2%80%AFAM.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06212821/Screenshot-2026-03-07-at-7.55.13%E2%80%AFAM.png"/></p>
<p><em>图片来源于 Shutterstock</em></p>

诺和诺德公司

<p>诺和诺德公司与 Hims & Hers Health reportedly 已解决其法律争端，并计划宣布在 Hims 的远程医疗平台上销售诺和诺德的减肥药物的合作关系。这一消息导致 Hims 的股价大幅上涨，在盘后交易中飙升近 40%。此次合作是在诺和诺德因与其减肥药物的复合版本相关的专利侵权提起诉讼后达成的。肥胖药物市场竞争日益激烈，FDA 对仿制产品的审查也在加大</p>

<p><strong>Novo Nordisk AS</strong> (NYSE: NVO) and <strong>Hims &amp; Hers Health Inc.</strong> (NYSE: HIMS) have reportedly ended their public feud, with the drugmaker deciding to sell its weight-loss drug on the telehealth platform.</p>
<div class="lb-trans"><p><strong>诺和诺德公司</strong> (NYSE: NVO) 和 <strong>Hims &amp; Hers Health Inc.</strong> (NYSE: HIMS) 据报道已经 结束了他们的公开争执，制药公司决定在远程医疗平台上销售其减肥药。</p>
</div><p>The announcement regarding the new partnership is expected as soon as Monday, Bloomberg reported on Friday, citing a person familiar with the matter.</p>
<div class="lb-trans"><p>关于新合作伙伴关系的公告预计将在周一尽快发布，彭博社 报道 周五援引一位知情人士的话说。</p>
</div><p>Last month, Novo Nordisk sued Hims &amp; Hers after the latter began marketing a compounded version of its new weight-loss pill. The company alleged patent violations, citing the ingredient used in Wegovy.</p>
<div class="lb-trans"><p>上个月，诺和诺德起诉了 Hims &amp; Hers，因为后者开始推广其新减肥药的复合版本。该公司指控侵犯专利，引用了 Wegovy 中使用的成分。</p>
</div><p>In 2025, Novo Nordisk and Hims &amp; Hers also announced a partnership, but the drugmaker ended the agreement abruptly after the platform declined to stop promoting the compounded versions of the drugs.</p>
<div class="lb-trans"><p>在 2025 年，诺和诺德和 Hims &amp; Hers 也宣布了一项合作关系，但在平台拒绝停止推广复合 药物版本 后，制药公司突然终止了协议。</p>
</div><p>“We are always in conversation with companies that can help improve patient access to FDA-approved medicines for people living with chronic diseases. These talks happen on an ongoing basis, and we will discuss if/when we have final details to share,” a Novo Nordisk spokesperson told Benzinga in an emailed statement.</p>
<div class="lb-trans"><p>“我们始终与能够帮助改善慢性疾病患者获得 FDA 批准药物的公司进行对话。这些谈话是持续进行的，我们将在有最终细节可分享时进行讨论，” 诺和诺德的一位发言人通过电子邮件告诉 Benzinga。</p>
</div><p>Hims &amp; Hers did not immediately respond to Benzinga's request for comment.</p>
<div class="lb-trans"><p>Hims &amp; Hers 并未立即回应 Benzinga' 的评论请求。</p>
</div><h2><strong>Weight-Loss Drug Market Pressure Builds</strong></h2>
<div class="lb-trans"><h2><strong>减肥药市场压力加大</strong></h2>
</div><p>Novo Nordisk has been facing tough competition in the obesity drugs market. The company's biggest rival is <strong>Eli Lilly and Company</strong> (NYSE: LLY) and telehealth platforms that offer compounded versions of GLP-1 drugs.</p>
<div class="lb-trans"><p>诺和诺德在肥胖药物市场面临激烈竞争。该 公司的最大竞争对手 是 <strong>礼来公司</strong> (NYSE: LLY) 和提供复合 GLP-1 药物版本的远程医疗平台。</p>
</div><p>The competition has grown due to the recent supply shortages. However, the U.S. Food and Drug Administration has indicated plans to increase scrutiny of copycat weight-loss drugs.</p>
<div class="lb-trans"><p>由于近期供应短缺，竞争加剧。然而，美国食品药品监督管理局已表示计划加强对仿制减肥药的审查。</p>
</div><p><strong>Price Action:</strong> After-hours trading saw shares of Hims &amp; Hers Health surge 39.77% to $22, after closing Friday down 0.88% at $15.74. Shares of Novo Nordisk closed at $38.58 on Friday, down 1.25%, but rose 2.12% to $39.40 in after-hours trading, according to Benzinga Pro.</p>
<div class="lb-trans"><p><strong>价格动态：</strong> 在盘后交易中，Hims &amp; Hers Health 的股价上涨 39.77%，至 22 美元，而周五收盘时下跌 0.88%，为 15.74 美元。诺和诺德的股价周五收于 38.58 美元，下跌 1.25%，但在盘后交易中上涨 2.12%，至 39.40 美元，数据来自 Benzinga Pro。</p>
</div><p><strong>Benzinga's Edge Stock Rankings</strong> show that Novo Nordisk is exhibiting weakness across the short, medium, and long-term, although its Quality score ranks in the 76th percentile.</p>
<div class="lb-trans"><p><strong>Benzinga 的边际股票排名</strong> 显示诺和诺德在短期、中期和长期内 表现疲软，尽管其质量评分在 76 百分位。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06212821/Screenshot-2026-03-07-at-7.55.13%E2%80%AFAM.png" alt="" original-src="https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06212821/Screenshot-2026-03-07-at-7.55.13%E2%80%AFAM.png"/></p>
<p><em>Image via Shutterstock</em></p>
<div class="lb-trans"><p><em>图片来源于 Shutterstock</em></p>
</div>

据报道，诺和诺德公司与 Hims & Hers 通过一项意外的减肥药协议，结束了激烈的法律争端